Knowlden J - Search Results

1

Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896.

Nicholson RI, Gee JM, Bryant S, Francis AB, McClelland RA, Knowlden J, Wakeling AE, Osborne CK. Nicholson RI, et al. Among authors: knowlden j. Ann N Y Acad Sci. 1996 Apr 30;784:325-35. doi: 10.1111/j.1749-6632.1996.tb16247.x. Ann N Y Acad Sci. 1996. PMID: 8651581 Review. No abstract available.

2

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Nicholson RI, et al. Among authors: knowlden jm. Endocr Relat Cancer. 2001 Sep;8(3):175-82. doi: 10.1677/erc.0.0080175. Endocr Relat Cancer. 2001. PMID: 11566608 Review.

3

Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Nicholson RI, et al. Among authors: knowlden jm. Ann N Y Acad Sci. 2002 Jun;963:104-15. doi: 10.1111/j.1749-6632.2002.tb04101.x. Ann N Y Acad Sci. 2002. PMID: 12095935

4

The biology of antihormone failure in breast cancer.

Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I. Nicholson RI, et al. Among authors: knowlden j. Breast Cancer Res Treat. 2003;80 Suppl 1:S29-34; discussion S35. doi: 10.1023/a:1025467500433. Breast Cancer Res Treat. 2003. PMID: 14535532 Review.

5

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Knowlden JM, et al. Endocrinology. 2003 Mar;144(3):1032-44. doi: 10.1210/en.2002-220620. Endocrinology. 2003. PMID: 12586780

6

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI. Hutcheson IR, et al. Breast Cancer Res Treat. 2003 Sep;81(1):81-93. doi: 10.1023/A:1025484908380. Breast Cancer Res Treat. 2003. PMID: 14531500

7

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.

Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nicholson RI, et al. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):346S-54S. doi: 10.1158/1078-0432.ccr-031206. Clin Cancer Res. 2004. PMID: 14734490

8

Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy.

Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D, Gee JM, Nicholson RI. Hutcheson IR, et al. Among authors: knowlden jm. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S89-97. doi: 10.1677/erc.1.01279. Endocr Relat Cancer. 2006. PMID: 17259562 Review.

9

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI. Hutcheson IR, et al. Among authors: knowlden jm. Breast Cancer Res. 2007;9(4):R50. doi: 10.1186/bcr1754. Breast Cancer Res. 2007. PMID: 17686159 Free PMC article.

10

Differential expression of oestrogen regulated genes in breast cancer.

Manning DL, McClelland RA, Knowlden JM, Bryant S, Gee JM, Green CD, Robertson JF, Blamey RW, Sutherland RL, Ormandy CJ, et al. Manning DL, et al. Among authors: knowlden jm. Acta Oncol. 1995;34(5):641-6. doi: 10.3109/02841869509094041. Acta Oncol. 1995. PMID: 7546832

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

40 results

Search Page